Lobbying Update: $30,000 of ATARA BIOTHERAPEUTICS INC. lobbying was just disclosed

$30,000 of ATARA BIOTHERAPEUTICS INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Advocacy related to healthcare, FDA, and biotechnology"

You can find more data on corporate lobbying on Quiver Quantitative.

ATRA Insider Trading Activity

ATRA insiders have traded $ATRA stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales.

Here’s a breakdown of recent trading of $ATRA stock by insiders over the last 6 months:

• JILL HENRICH (EVP, Chief Regulatory Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 1,963 shares.
• ERIC J HYLLENGREN (EVP, CFO and COO) has traded it 3 times. They made 0 purchases and 3 sales, selling 2,434 shares.
• ANHCO NGUYEN (President and CEO) has traded it 4 times. They made 0 purchases and 4 sales, selling 3,485 shares.
• PASCAL TOUCHON (President and CEO) has traded it 2 times. They made 0 purchases and 2 sales, selling 3,038 shares.
• AMAR MURUGAN (EVP, Chief Legal Officer) has traded it 3 times. They made 0 purchases and 3 sales, selling 1,158 shares.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

ATRA Hedge Fund Activity

We have seen 0 institutional investors add shares of ATRA stock to their portfolio, and 0 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

• EVERSOURCE WEALTH ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2024

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.